Gilead’s block­buster ADC Trodelvy fails blad­der can­cer con­fir­ma­to­ry study

Gilead on Thurs­day dis­closed that Trodelvy, the an­ti­body-drug con­ju­gate that is a key part of the drug­mak­er’s on­col­o­gy busi­ness, failed a Phase 3 study af­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.